Merck 2008 Annual Report Download - page 46

Download and view the complete annual report

Please find page 46 of the 2008 Merck annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 153

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153

MANAGEMENT REPORT OF THE MERCK GROUP 41
24 Responsibility
26 Merck shares
30 Pharmaceuticals business sector
50 Chemicals business sector
12 Overall economic situation
14 Economic development
of Merck
15 Financial position and results
of operations
60 Corporate and Other
61 Risk report
64 Report on expected developments
64 Subsequent events
Status of our innovative compounds (Status: December 31, 2008)
Therapeutic area Compound Indication Status
Oncology Erbitux® (cetuximab)1NSCLC Filed
Adjuvant colorectal cancer Phase III
Gastric cancer Phase III
Stimuvax® 2NSCLC Phase III
Cilengitide Glioblastoma Phase III
Erbitux® (cetuximab)1Breast cancer Phase II
Cilengitide SCCHN Phase II
Tucotuzumab celmoleukin
(EMD 273066 / huKS-IL2)
SCLC Phase II
EMD 273063 (hu14.18-IL2) Pediatric neuroblastoma
and melanoma
Phase II
Adecatumumab (MT201)3Solid tumors Phase I
Aurorakinase inhibitor (AS703569)4Solid tumors and hematological malignancies Phase I
NHS-IL2-LT (EMD 521873) Solid tumors Phase I
DI17E6 (EMD 525797) Solid tumors Phase I
Eg 5 inhibitor (EMD 534085) Solid tumors und hematological malignancies Phase I
Survivac (cancer vaccine) Solid tumors Phase I
MEK inhibitor (AS703026)5Solid tumors Phase I
IMO-20556
(TLR9 immunomodulator)
Solid tumors Phase I
Sonepcizumab (ASONEP™)
7Solid tumors Phase I
Neurodegenerative
Diseases
New formulation of Rebif® Relapsing forms of multiple sclerosis (MS) EMEA: approved;
FDA: filed
Approved/
filed
Clinically isolated syndrome Phase III
Cladribine tablets Relapsing forms of MS Phase III
Clinically isolated syndrome Phase III
Safinamide8Early-stage Parkinson’s disease Phase III
Mid- to late-stage Parkinson’s disease Phase III
Atacicept9Multiple sclerosis Phase II
Autoimmune &
Inflammatory Diseases
Atacicept9Systemic lupus erythematosus Phase III
Rheumatoid arthritis Phase II
Fibroblast growth factor 18 9 Osteoarthritis Phase I
Fertility Hyperglycosylated FSH Infertility (OI / ART) Phase II
Endocrinology Tesmarolin10 HIV patients with lipodystrophy (only U.S.) Phase III
ARX 20111 Growth hormone deficiency Phase I
1 Developed in cooperation with mit ImClone: Erbitux® is
a trademark of ImClone Systems, a wholly owned sub-
sidiary of Eli Lilly & Co.
2 Exclusive worldwide licensing rights acquired from
Oncothyreon Inc.
3 Collaboration with Micromet AG
4 Collaboration with Rigel Pharmaceuticals Inc.
5 All rights acquired from Santhera Pharmaceuticals AG
6
Inlicensed from Idera Pharmaceuticals Inc.
7
Collaboration with LPath, Inc.
ASONEP is a trademark of LPath, Inc.
8
Collaboration with Newron Pharmaceuticals S.p.A.
9
Collaboration with ZymoGenetics Inc.
10 Collaboration with Theratechnologies
11 Collaboration with Ambrx, Inc.
SCCHN: Squamous cell carcinoma of the head and neck
NSCLC: Non-small cell lung cancer
SCLC: Small cell lung cancer
OI/ART: Ovulation induction/Assisted reproductive
technology
HARS: HIV-associated adipose redistribution syndrome